iRadimed Corporation (NASDAQ:IRMD) Given Consensus Recommendation of “Buy” by Analysts

iRadimed Corporation (NASDAQ:IRMD) has been assigned an average rating of “Buy” from the five research firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation, three have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $120.00.

A number of analysts have recently issued reports on the stock. Lake Street Capital reissued a “buy” rating and issued a $120.00 price objective on shares of iRadimed in a research note on Wednesday, February 11th. Freedom Capital raised shares of iRadimed to a “strong-buy” rating in a research note on Thursday, April 2nd. Finally, Roth Mkm reissued a “buy” rating and issued a $120.00 price objective on shares of iRadimed in a research note on Tuesday, February 10th.

iRadimed Trading Up 4.4%

Shares of IRMD stock opened at $87.15 on Friday. iRadimed has a 12 month low of $50.31 and a 12 month high of $107.90. The stock has a market cap of $1.11 billion, a P/E ratio of 49.80 and a beta of 0.91. The company has a 50 day simple moving average of $96.69 and a two-hundred day simple moving average of $93.87.

iRadimed (NASDAQ:IRMD) last announced its earnings results on Friday, May 1st. The medical equipment provider reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.03. The business had revenue of $21.98 million during the quarter, compared to analysts’ expectations of $21.32 million. iRadimed had a net margin of 26.82% and a return on equity of 23.83%. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. As a group, equities analysts forecast that iRadimed will post 1.94 earnings per share for the current year.

iRadimed Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 29th. Stockholders of record on Friday, May 15th will be paid a $0.20 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. iRadimed’s dividend payout ratio is 45.71%.

Insider Activity

In other news, CEO Roger E. Susi sold 3,750 shares of the stock in a transaction on Monday, April 27th. The shares were sold at an average price of $89.16, for a total value of $334,350.00. Following the completion of the sale, the chief executive officer directly owned 2,198,750 shares of the company’s stock, valued at $196,040,550. This represents a 0.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 48,750 shares of company stock valued at $4,708,950 over the last three months. Corporate insiders own 36.80% of the company’s stock.

Institutional Trading of iRadimed

Hedge funds and other institutional investors have recently modified their holdings of the company. SG Americas Securities LLC grew its stake in iRadimed by 88.6% during the fourth quarter. SG Americas Securities LLC now owns 70,391 shares of the medical equipment provider’s stock valued at $6,848,000 after acquiring an additional 33,072 shares in the last quarter. Principal Financial Group Inc. purchased a new position in iRadimed during the third quarter valued at $422,000. Tudor Investment Corp ET AL purchased a new position in iRadimed during the third quarter valued at $666,000. R Squared Ltd purchased a new position in iRadimed during the third quarter valued at $308,000. Finally, Nkcfo LLC purchased a new position in iRadimed during the third quarter valued at $96,000. 92.34% of the stock is owned by hedge funds and other institutional investors.

iRadimed News Summary

Here are the key news stories impacting iRadimed this week:

• Positive Sentiment: Q1 earnings and revenue beat consensus: iRadimed reported non?GAAP EPS of $0.49 (GAAP $0.45) and revenue of ~$22.0M, both above expectations, with year?over?year EPS and revenue growth — a primary driver of the intraday rally. iRadimed (IRMD) Beats Q1 Earnings and Revenue Estimates
• Positive Sentiment: Record GAAP and improved margins: management highlighted record GAAP diluted EPS and improved net margin/ROE metrics, signaling operating leverage and pricing/volume strength. IRADIMED Reports First Quarter 2026 Financial Results
• Positive Sentiment: Dividend increase maintained: the company announced a regular quarterly cash dividend of $0.20 (up from $0.17), which supports income-oriented investors and signals confidence in cash flow. IRADIMED Reports First Quarter 2026 Financial Results
• Neutral Sentiment: Full?year guidance reaffirmed and nudged slightly above consensus: FY2026 EPS guidance was set to $2.06–$2.21 (consensus ~2.05), and revenue guidance roughly $91–96M (consensus ~$92.4M) — supportive but not a major beat. IRADIMED Reports First Quarter 2026 Financial Results
• Neutral Sentiment: CEO insider sale disclosed: CEO Roger Susi sold 3,750 shares under a pre?arranged Rule 10b5?1 plan — a small, orderly sale that management says was planned, so likely neutral for most investors. Insider Selling: iRadimed CEO Sells Shares
• Negative Sentiment: Q2 revenue and mid?point EPS guidance slightly cautious vs. street: Q2 revenue guidance of $20.0–$21.0M is modestly below consensus (~$21.1M) and Q2 EPS guidance (0.44–0.48) straddles the street estimate — this introduces short?term execution risk that could temper gains. IRADIMED Reports First Quarter 2026 Financial Results

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.